Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
Provided By GlobeNewswire
Last update: May 13, 2025
WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced first quarter 2025 financial results and recent developments.
Read more at globenewswire.com
